Tenaya Therapeutics (TNYA) is back in focus after reporting a full year 2025 net loss of US$90.6 million, alongside fresh preclinical data and a new collaboration in cardiovascular and muscular disease programs.
See our latest analysis for Tenaya Therapeutics.
The recent MDA 2026 data for TN-301 and the new Alnylam collaboration appear to have sharpened market focus, with a 7 day share price return of 47.70% standing in contrast to a 36.86% decline over 90 days and a 3 year total shareholder return of 67.29%.
If this kind of early stage biotech news has caught your attention, it could be a good moment to see what else is moving using our screener of 34 healthcare AI stocks.
With the stock at US$0.86 after a sharp 7 day rebound, yet still showing a 3 year total shareholder return of 67.29%, investors may ask whether Tenaya is still underappreciated or whether markets are already pricing in future growth.
Preferred Price-to-Book of 2.2x: Is it justified?
At a last close of $0.86, Tenaya screens as relatively cheap on one of the few metrics that applies to a pre revenue, loss making biotech, its P/B ratio of 2.2x.
P/B compares the company’s market value to the net assets on its balance sheet, which can be a useful reference point when earnings are negative and revenue is still at $0.
For Tenaya, the data suggests the market is assigning a lower P/B than both peers and the broader US biotech group. This may reflect investor caution around funding, cash runway and the time required to turn its gene therapy and small molecule programs into commercial products.
Compared with a peer average P/B of 5x and a US Biotechs industry average of 2.7x, Tenaya’s 2.2x ratio sits at a discount. This implies the market is valuing its asset base more conservatively than many comparables.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 2.2x (UNDERVALUED)
However, that discount could unwind quickly if clinical data underwhelms or if funding becomes harder to secure while Tenaya continues to report annual net losses.
Find out about the key risks to this Tenaya Therapeutics narrative.
Next Steps
The mix of risks and rewards here is hard to ignore, so it makes sense to look through the data yourself and move quickly while sentiment evolves. Our breakdown of 1 key reward and 4 important warning signs can help you weigh both sides before you decide your next step.
Looking for more investment ideas?
If Tenaya has sparked your interest, do not stop here. Use the screener to spot other opportunities that could suit your style before they move without you.
- Target resilient names with 67 resilient stocks with low risk scores that keep risk scores in check while you focus on building your portfolio with more confidence.
- Hunt for potential bargains using our list of 50 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet.
- Seek steady income ideas through 14 dividend fortresses and quickly see which companies offer higher yields alongside an emphasis on stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com